Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing therapeutics for Parkinson's disease and related disorders. The company operates principally in Boston, Massachusetts. Inhibikase Therapeutics Inc. is headquartered in Atlanta, Georgia.
| Revenue (Most Recent Fiscal Year) | $0.26M |
| Net Income (Most Recent Fiscal Year) | $-48.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -46.90% |
| Return on Assets (Trailing 12 Months) | -43.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 21.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 21.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.48 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 132.03M |
| Free Float | 122.39M |
| Market Capitalization | $241.62M |
| Average Volume (Last 20 Days) | 1.16M |
| Beta (Past 60 Months) | 0.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.81% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |